Table 1.
Inclusion, exclusion and withdrawal criteria
Figure 1.
Patient flow scheme.
Table 2.
Subject characteristics at enrolment (−1 month) for 100 patients with type-1 diabetes.
Table 3.
Metabolism-related variables in 100 patients with type-1 diabetes before and after one year of treatment with metformin or placebo.
Table 4.
Reported hypoglycaemic episodes in patients with type-1 diabetes during one year of treatment with metformin or placebo.
Table 5.
Non-hypoglycaemia-related serious adverse events in 100 patients with type-1 diabetes allocated treatment with metformin or placebo for one year.
Table 6.
Effect of metformin versus placebo on follow-up (intermediate and study visit) levels of HbA1c and insulin doses in 72 patients with type-1 diabetes during a one year period.